Hepatic steatosis is associated with nonalcoholic fatty liver disease (NAFLD), which can progress to nonalcoholic steatohepatitis (NASH). NAFLD is also a leading risk factor for the development of impaired fasting glucose and type 2 diabetes. Small heterodimer partner (SHP, NR0B2) belongs to the nuclear hormone receptor superfamily. Earlier molecular studies suggested that SHP plays a role in glucose and lipid metabolism. Our studies with congenic SHP-/- mice showed that SHP regulates hepatic triglyceride (TG) storage in response to excess dietary fat ingestion, and its deficiency protects against development of hepatic steatosis. This protection against fatty liver development in SHP-/- mice results in part from elevated-fatty acid oxidation due to derepression of PPAR? transcriptional activity, but also to lower expression of PPAR?2, a major lipogenic transcription factor. Marked elevation of hepatic PPAR? expression has been observed in numerous mouse models of NAFLD and human patients with the disorder. Integrating our own preliminary results with published studies, we have identified a novel transcriptional cascade in which SHP regulates PPAR? expression. In this new regulatory pathway, SHP represses the ability of the retinoic acid receptor (RAR) to activate expression of hairy and enhancer split 6 (Hes6) a transcriptional corepressor that has recently been reported to repress PPAR?2 via inhibition of HNF4? transactivation. In accord with this, we have shown that RAR activation by its natural ligand all-trans retinoic acid (atRA) alleviates hepatic steatosis. Thus we hypothesize that SHP and atRA/RAR can function coordinately to regulate hepatic lipid accumulation. In order to critically test the significance o our proposed regulatory cascade, we will 1) define the regulatory role of SHP and atRA in the expression of Hes6, then 2) examine the functional interactions of SHP and atRA/RAR in modulating fat accumulation in mouse models of NAFLD, and finally 3) test the linkage between Hes6 and fat mobilization using Hes6 overexpression or silencing. Our studies of this novel transcriptional regulatory network will provide insights into the development of hepatic steatosis and crucial avenues into the prevention and treatment of a disorder that is a major contributor in the development of the metabolic syndrome.
The proposed project will focus on the establishment of a transcriptional regulatory cascade controlling hepatic lipid homeostasis. The novel cascade initiated by coordinate action of SHP and all trans retinoic acid consists of orphan nuclear receptor HNF4?, its novel repressor Hes6, and adipogenic nuclear hormone receptor PPAR?2. A solid establishment of the linkage between the proposed transcriptional regulatory cascade and lipid mobilization will provides insights into the development of therapeutic approaches to treat fatty liver diseases.
|Akinrotimi, Oludemilade; Riessen, Ryan; VanDuyne, Philip et al. (2017) Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice. Hepatology 66:1854-1865|
|You, Min; Jogasuria, Alvin; Lee, Kwangwon et al. (2017) Signal Transduction Mechanisms of Alcoholic Fatty Liver Disease: Emer ging Role of Lipin-1. Curr Mol Pharmacol 10:226-236|
|Palmisano, Brian T; Le, Thao D; Zhu, Lin et al. (2016) Cholesteryl ester transfer protein alters liver and plasma triglyceride metabolism through two liver networks in female mice. J Lipid Res 57:1541-51|
|Park, Jung Eun; Lee, Mikang; Mifflin, Ryan et al. (2016) Enhanced ethanol catabolism in orphan nuclear receptor SHP-null mice. Am J Physiol Gastrointest Liver Physiol 310:G799-807|
|Pan, Xian; Lee, Yoon-Kwang; Jeong, Hyunyoung (2015) Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner. Drug Metab Dispos 43:1002-7|
|Kim, Seong Chul; Kim, Chun-Ki; Axe, David et al. (2014) All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. Hepatology 59:1750-60|
|Hardwick, James P; Eckman, Katie; Lee, Yoon Kwang et al. (2013) Eicosanoids in metabolic syndrome. Adv Pharmacol 66:157-266|